TransCode Therapeutics Inc (NASDAQ:RNAZ) price on Thursday, March 20, rose 1.32% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.77.
A look at the stock’s price movement, the close in the last trading session was $0.76, moving within a range at $0.76 and $0.86. The beta value (5-Year monthly) was 1.153. Turning to its 52-week performance, $66.33 and $0.64 were the 52-week high and 52-week low respectively. Overall, RNAZ moved -92.19% over the past month.
TransCode Therapeutics Inc’s market cap currently stands at around $0.54 million, with investors looking forward to this quarter’s earnings report slated for on 2024-Nov-13.
Analysts have a consensus estimate of 300k for the company’s revenue for the quarter, with a low and high estimate of 300k and 300k respectively.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RNAZ is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
RNAZ’s current price about -65.02% and -85.15% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 26.61, while 7-day volatility ratio is 19.14% and 24.70% in the 30-day chart. Further, TransCode Therapeutics Inc (RNAZ) has a beta value of 1.40, and an average true range (ATR) of 0.78.
If we refocus on TransCode Therapeutics Inc (NASDAQ:RNAZ), historical trading data shows that trading volumes averaged 4.52 over the past 10 days and 2.57 million over the past 3 months. The company’s latest data on shares outstanding shows there are 0.70 million shares.
The 5.08% of TransCode Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 26.18% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.54 million on 2025-02-28, giving us a short ratio of 0.16. The data shows that as of 2025-02-28 short interest in TransCode Therapeutics Inc (RNAZ) stood at 7769.9995 of shares outstanding, with shares short rising to 0.37 million registered in 2025-01-31. Current price change has pushed the stock -77.15% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RNAZ stock continues to rise going into the next quarter.
